In Crohn’s Disease, More Research Needed on Tests Before Actual Treatment, UK’s Health Service Says

In Crohn’s Disease, More Research Needed on Tests Before Actual Treatment, UK’s Health Service Says
The United Kingdom's National Institute for Health and Care Excellence (NICE) recently published recommendations on new diagnostic tests to guide treatment in patients with Crohn’s disease, suggesting that more research is needed before such tests can be used routinely in the U.K.'s National Health Service. Crohn's disease is a chronic, relapsing-remitting inflammatory bowel disease (IBD) that causes inflammation in the digestive system. So far, there is no cure. Symptoms include diarrhea, abdominal pain and cramping, exhaustion, and weight loss. The LISA-TRACKER ELISAs (Theradiag), IDKmonitor ELISAs (Immundiagnostik AG), and Promonitor ELISAs (Proteomika S.L.U) are currently used in the diagnostics of Crohn’s disease, particularly by measuring the levels of TNF-alpha inhibitors and antibodies against them. TNF-alpha inhibitors can stop the inflammatory response in the intestines, a characteristic of Crohn’s disease. Some patients with Crohn’s do not respond to treatment with TNF-alpha inhibitors, and many patients who initially respond to treatment eventually become non-responsive over time. This is explained by changes in disease progression and characteristics, inflammation dissociated to TNF concentrations, the presence of antibodies against TNF-alpha inhibitors, or even fluctuating drug levels. The regimen and dose of TNF-alpha inhibitor treatment is difficult to define, and tre
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *